Jubilant Organosys Ltd, headquartered in India, announced that its subsidiary Draximage Ltd has signed an agreement with France-based Guerbet for the distribution of its nuclear medicine products in Europe.

Swiss drug maker Roche has agreed to acquire the remaining outstanding shares of US entity Genentech for $46.8 billion, making it the third largest deal in the global pharma industry in less than two months. “Roche will acquire the outstanding publicly held interest in Genentech for $95 per share in cash, or a total payment of approximately $46.8 billion to equity holders of Genentech other than Roche," the two firms said in a statement.

Gilead Sciences Inc. agreed to buy CV Therapeutics Inc. for about $1.4 billion to gain chest-pain and heart drugs, topping a hostile offer from Japan’s Astellas Pharma Inc.

Teikoku Pharma USA Inc., the international specialty pharmaceutical company, announces that it has signed an exclusive worldwide (excluding Japan) licensing agreement with Eisai Co., Ltd. to develop and commercialize a new transdermal formulation of donepezil, a leading compound for the treatment of Alzheimer's disease in the world.